KR20100032854A - 아스피린 민감성 및 다른 군의 심혈관 질환 치료를 위한 ｔｐ 조절자의 용도 - Google Patents

아스피린 민감성 및 다른 군의 심혈관 질환 치료를 위한 ｔｐ 조절자의 용도 Download PDF

Info

Publication number
KR20100032854A
KR20100032854A KR1020097025329A KR20097025329A KR20100032854A KR 20100032854 A KR20100032854 A KR 20100032854A KR 1020097025329 A KR1020097025329 A KR 1020097025329A KR 20097025329 A KR20097025329 A KR 20097025329A KR 20100032854 A KR20100032854 A KR 20100032854A
Authority
KR
South Korea
Prior art keywords
aspirin
modulator
subject
sensitive
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097025329A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 알. 필립스
패트릭스 앙드레
찰스 제이. 홈씨
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20100032854A publication Critical patent/KR20100032854A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097025329A 2007-05-03 2008-05-02 아스피린 민감성 및 다른 군의 심혈관 질환 치료를 위한 ｔｐ 조절자의 용도 Withdrawn KR20100032854A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US91578407P 2007-05-03 2007-05-03
US91578507P 2007-05-03 2007-05-03
US60/915,785 2007-05-03
US60/915,784 2007-05-03
US94731607P 2007-06-29 2007-06-29
US94728907P 2007-06-29 2007-06-29
US60/947,289 2007-06-29
US60/947,316 2007-06-29

Publications (1)

Publication Number Publication Date
KR20100032854A true KR20100032854A (ko) 2010-03-26

Family

ID=39943967

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097025329A Withdrawn KR20100032854A (ko) 2007-05-03 2008-05-02 아스피린 민감성 및 다른 군의 심혈관 질환 치료를 위한 ｔｐ 조절자의 용도
KR1020097025330A Withdrawn KR20100037029A (ko) 2007-05-03 2008-05-02 트롬복세인 수용체 길항제를 사용하여 혈전을 치료 및 예방하기 위한 단위 투약 제형 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097025330A Withdrawn KR20100037029A (ko) 2007-05-03 2008-05-02 트롬복세인 수용체 길항제를 사용하여 혈전을 치료 및 예방하기 위한 단위 투약 제형 및 방법

Country Status (10)

Country Link
US (2) US20090012136A1 (enExample)
EP (2) EP2146573A4 (enExample)
JP (2) JP2010526104A (enExample)
KR (2) KR20100032854A (enExample)
CN (2) CN101686668A (enExample)
AU (2) AU2008247441A1 (enExample)
CA (2) CA2688319A1 (enExample)
IL (2) IL201885A0 (enExample)
MX (2) MX2009011745A (enExample)
WO (2) WO2008137791A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders
WO2008087371A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
AU2012336036A1 (en) 2011-11-07 2014-06-19 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
JP6183459B2 (ja) * 2012-08-06 2017-08-23 Jnc株式会社 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
JP6273072B2 (ja) 2014-05-16 2018-01-31 カンバーランド ファーマシューティカルズ，インコーポレーテッド イフェトロバンにより心臓線維症を治療する組成物及び方法
ES2858551T3 (es) * 2015-06-16 2021-09-30 Atxa Therapeutics Ltd Antagonistas del receptor de tromboxano
JP7033454B2 (ja) * 2015-06-30 2022-03-10 カンバーランド ファーマシューティカルズ，インコーポレーテッド Ａｅｒｄ／喘息におけるトロンボキサン受容体拮抗薬
WO2017197107A1 (en) 2016-05-11 2017-11-16 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
AU2021246444A1 (en) * 2020-03-31 2022-10-20 Martin Ogletree Methods and pharmaceutical compositions of thromboxane A2 receptor antagonist for the treatment of COVID-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895115A (en) * 1974-03-01 1975-07-15 Serono Ist Farm Method of inhibiting platelet aggregation
US5071866A (en) * 1989-07-31 1991-12-10 Bristol-Myers Squibb Company Arylpyrazole derivatives as anti-platelet agents
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
CN1665538A (zh) * 2002-07-09 2005-09-07 B·M·R·A·有限公司 血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
CN101686668A (zh) 2010-03-31
EP2144999A1 (en) 2010-01-20
KR20100037029A (ko) 2010-04-08
US20090012115A1 (en) 2009-01-08
AU2008247441A1 (en) 2008-11-13
EP2146573A4 (en) 2012-11-21
IL201886A0 (en) 2010-06-16
WO2008137793A1 (en) 2008-11-13
MX2009011744A (es) 2010-02-12
CA2688319A1 (en) 2008-11-13
EP2144999A4 (en) 2010-06-16
WO2008137791A1 (en) 2008-11-13
AU2008247439A1 (en) 2008-11-13
JP2010527331A (ja) 2010-08-12
MX2009011745A (es) 2010-02-12
CA2688317A1 (en) 2008-11-13
IL201885A0 (en) 2011-08-01
US20090012136A1 (en) 2009-01-08
JP2010526104A (ja) 2010-07-29
EP2146573A1 (en) 2010-01-27
CN101711279A (zh) 2010-05-19

Similar Documents

Publication Publication Date Title
KR20100032854A (ko) 아스피린 민감성 및 다른 군의 심혈관 질환 치료를 위한 ｔｐ 조절자의 용도
US20090192123A1 (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors
Mazaleuskaya et al. Druggable prostanoid pathway
CA2413705A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US10314824B2 (en) Compositions and methods of treating cardiac fibrosis with ifetroban
AU2011279144A1 (en) Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP2011515469A (ja) シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
US9132191B2 (en) Compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease
ES2395002T3 (es) Nueva combinación para uso en el tratamiento de trastornos inflamatorios
JP2006509720A (ja) 潰瘍治療用プロトンポンプ阻害剤としての環付加ピロール化合物
KR20110103428A (ko) 분비성 포스포리파제 Ａ２ （ｓＰＬＡ２） 억제제 또는 ｓＰＬＡ２ 억제제 조합 치료요법을 이용한 주요 유해 심장 사건 및 급성 관상동맥 증후군의 치료
US20230129262A1 (en) Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19
AU2017219121A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
KR20040053884A (ko) 급성 관상동맥증후군 및 관련 상태의 치료를 위한항혈소판제와 병용하는 멜록시캄의 용도
HK40037282A (en) Compositions and methods of treating cardiac fibrosis with ifetroban
CA2734870A1 (en) Therapeutic agent for anca-related vasculitis
HK1249399A1 (zh) 用伊非曲班治療心臟纖維化的組合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid